Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Numéro 8-9, Août–Septembre 2013
Page(s) 785 - 790
Section Diabète : approches thérapeutiques émergentes
DOI https://doi.org/10.1051/medsci/2013298019
Publié en ligne 5 septembre 2013
  1. Bartel DP. MicroRNAs : genomics, biogenesis, mechanism, and function. Cell 2004 ; 116 : 281–297. [CrossRef] [PubMed]
  2. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004 ; 432 : 226–230. [CrossRef] [PubMed]
  3. Poy MN, Hausser J, Trajkovski M, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA 2009 ; 106 : 5813–5818. [CrossRef]
  4. El Ouaamari A, Baroukh N, Martens GA, et al. miR-375 targets 3’-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008 ; 57 : 2708–2717. [CrossRef] [PubMed]
  5. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005 ; 37 : 495–500. [CrossRef] [PubMed]
  6. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 2008 ; 389 : 305–312. [CrossRef] [PubMed]
  7. Baroukh N, Ravier MA, Loder MK, et al. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 2007 ; 282 : 19575–19588. [CrossRef] [PubMed]
  8. Plaisance V, Abderrahmani A, Perret-Menoud V, et al. MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 2006 ; 281 : 26932–26942. [CrossRef] [PubMed]
  9. Roggli E, Gattesco S, Caille D, et al. Changes in microRNA expression contribute to pancreatic beta-cell dysfunction in prediabetic NOD mice. Diabetes 2012 ; 61 : 1742–1751. [CrossRef] [PubMed]
  10. Zhu H, Shyh-Chang N, Segre AV, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011 ; 147 : 81–94. [CrossRef] [PubMed]
  11. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci USA 2011 ; 108 : 21075–21080. [CrossRef]
  12. Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011 ; 474 : 649–653. [CrossRef] [PubMed]
  13. Ryu HS, Park SY, Ma D, et al. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS One 2011 ; 6 : e17343. [CrossRef] [PubMed]
  14. Davalos A, Goedeke L, Smibert P, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 2011 ; 108 : 9232–9237. [CrossRef]
  15. Pandey AK, Verma G, Vig S, et al. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol 332 : 125–133. [CrossRef] [PubMed]
  16. Liang J, Liu C, Qiao A, et al. MicroRNA-29a-c decrease fasting blood glucose levels by negatively regulating hepatic gluconeogenesis. J Hepatol 2013 ; 58 : 535–542. [CrossRef] [PubMed]
  17. Hasseine LK, Hinault C, Lebrun P, et al. miR-139 impacts FoxO1 action by decreasing FoxO1 protein in mouse hepatocytes. Biochem Biophys Res Commun 2009 ; 390 : 1278–1282. [CrossRef] [PubMed]
  18. Granjon A, Gustin MP, Rieusset J, et al. The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1c/myocyte enhancer factor 2C pathway. Diabetes 2009 ; 58 : 2555–2564. [CrossRef] [PubMed]
  19. Roggli E, Britan A, Gattesco S, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 2010 ; 59 : 978–986. [CrossRef] [PubMed]
  20. Ruan Q, Wang T, Kameswaran V, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci USA 2011 ; 108 : 12030–12051. [CrossRef]
  21. Lovis P, Roggli E, Laybutt DR, et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 2008 ; 57 : 2728–2736. [CrossRef] [PubMed]
  22. Li S, Chen X, Zhang H, et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res 2009 ; 50 : 1756–1765. [CrossRef] [PubMed]
  23. He A, Zhu L, Gupta N, et al. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007 ; 21 : 2785–2794. [CrossRef] [PubMed]
  24. Herrera BM, Lockstone HE, Taylor JM, et al. MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat model of type 2 diabetes. BMC Med Genomics 2009 ; 2 : 54. [CrossRef] [PubMed]
  25. Gallagher IJ, Scheele C, Keller P, et al. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2010 ; 2 : 9. [CrossRef] [PubMed]
  26. Kloting N, Berthold S, Kovacs P, et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One 2009 ; 3 : e4699. [CrossRef]
  27. Bolmeson C, Esguerra JL, Salehi A, et al. Differences in islet-enriched miRNAs in healthy and glucose intolerant human subjects. Biochem Biophys Res Commun 2011 ; 404 : 16–22. [CrossRef] [PubMed]
  28. Zhao H, Guan J, Lee HM, et al. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas 2010 ; 39 : 843–846. [CrossRef] [PubMed]
  29. Becker N, Lockwood CM. Pre-analytical variables in miRNA analysis. Clin Biochem 2013 ; doi : 10.1016/j.clinbiochem.2013.02.015.
  30. Jacovetti C, Abderrahmani A, Parnaud G, et al. MicroRNAs contribute to compensatory beta cell expansion during pregnancy and obesity. J Clin Invest 2012 ; 122 : 3541–3551. [CrossRef] [PubMed]
  31. Zampetaki A, Willeit P, Drozdov I, et al. Profiling of circulating microRNAs : from single biomarkers to re-wired networks. Cardiovasc Res 2012 ; 93 : 555–562. [CrossRef] [PubMed]
  32. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010 ; 107 : 810–817. [CrossRef] [PubMed]
  33. Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes : a clinical study. Acta Diabetol 2011 ; 48 : 61–69. [CrossRef] [PubMed]
  34. Erener S, Mojibian M, Fox JK, et al. Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 2013 ; 154 : 603–608. [CrossRef] [PubMed]
  35. Ladeiro Y, Zucman-Rossi J. Micro-ARN (miARN) et cancer : le cas des tumeurs hépatocellulaires. Med Sci (Paris) 2009 ; 25 : 467–472. [CrossRef] [EDP Sciences] [PubMed]
  36. Gauthier BR, Wollheim CB. MicroARN : ribo-régulateurs de l’homéostasie du glucose. Med Sci (Paris) 2006 ; 22 : 463–465. [CrossRef] [EDP Sciences] [PubMed]
  37. Duez H, Sebti Y, Staels B. Horloges circadiennes et métabolisme : intégration des signaux métaboliques et environnementaux. Med Sci (Paris) 2013 ; 29 : 772–777. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.